Precautions for use of sotorasibu (AMG 510) and important reminders during medication

Sotorasib (trade name: Lumakras, R&D code: AMG 510) is the world's first KRAS G12C inhibitor approved for marketing, specifically used to treat patients with KRAS Patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with G12Cmutations. As an important achievement of precision medicine, the emergence of sotoracib has filled the gap that KRAS mutations have been "undruggable" for a long time, providing new treatment hope for such patients. However, due to its unique mechanism of action and closely related efficacy and safety, patients need to follow a series of precautions while using sotoraxib to maximize benefits and reduce risks.

1. Precautions before taking medicine

Before sotoracib is officially used, genetic testing must be done to confirm the presence of the KRAS G12C mutation in the patient. KRAS G12C mutation. Only patients who meet this condition are likely to obtain significant benefits from the drug. In addition, doctors will also conduct a comprehensive assessment based on the patient's previous treatment history, liver and kidney function, comorbid diseases, and medication usage. For patients who have failed multiple lines of treatment or cannot tolerate traditional chemotherapy or immunotherapy, sotorasib often becomes an optional option for subsequent treatment.

Before taking the drug, patients need to undergo complete liver function, renal function and routine blood tests. Because the metabolism of sotorasib mainly depends on the liver, patients with poor liver function need to be particularly cautious. If a patient has severe liver disease, their doctor may need to adjust the dose or monitor them closely.

2. Usage methods and period reminders

Sotorracib is an oral preparation, and it is usually recommended to take 960mg once a day at a fixed time. Patients should swallow the tablets whole and avoid chewing, breaking or crushing the tablets to avoid affecting drug absorption and efficacy. You can choose to take the drug on an empty stomach or with a low-fat diet, but you need to avoid taking it with high-fat foods or drugs that affect the gastric acid environment (such as strong antacids), as this may change the bioavailability of sotorasibu.

If the patient misses a dose, he or she should take it as soon as possible. However, if the time before the next dose is less than 6 hours, the missed dose should be skipped to avoid repeated dosing.

3. Common side effects and monitoring points

Although sotoracib is generally well tolerated, it may still cause some side effects, the most common of which include:

1.Gastrointestinal reactions: such as diarrhea, nausea, and vomiting. Some patients may have severe symptoms that affect their appetite and nutritional intake. You should pay attention to a light diet, replenish water, and use antidiarrheal or antiemetic drugs under the guidance of a doctor if necessary.

2. Abnormal liver function: sotorasiib may cause ALT, AST rises, so liver function needs to be monitored regularly during the medication period, especially within the first 3 months, and should be reviewed every 2-4 weeks. If significant liver function damage occurs, your doctor may require you to temporarily stop taking the drug or reduce the dose.

3.Respiratory system reaction: Some patients may be at risk of dyspnea or interstitial pneumonia. If the patient develops persistent cough or shortness of breath while taking the medication, he or she should report to the doctor immediately and undergo lung imaging examination.

4.Fatigue and musculoskeletal discomfort: Some patients will feel fatigue, joint or muscle pain, which are usually mild to moderate symptoms, but if they continue to worsen, further evaluation is needed.

4. Interactions with other drugs

Sotorasiib is mainly metabolized in the body by CYP3A4 enzyme, so caution is required when combined with other drugs. For example:

StrongCYP3A4 inhibitors (such as clarithromycin, itraconazole) may increase the plasma concentration of sotoraxib and increase the risk of toxicity.

CYP3A4Inducers (such as rifampicin, carbamazepine) may reduce its efficacy.

Concomitant use with proton pump inhibitors (PPI) may reduce the absorption of sotoraxib, and should be avoided or the medication method should be adjusted as much as possible.

Therefore, patients should truthfully inform their doctors about all medications they are taking, including prescription drugs, over-the-counter drugs, herbal medicines, and health supplements, to avoid potential drug interactions.

5. Lifestyle and Diet Suggestions

During the period of using sotoracib, patients need to maintain a regular life, avoid overexertion, and enhance their own immunity. The diet should be light and easy to digest, and eat less spicy and greasy food to reduce gastrointestinal discomfort. At the same time, you must quit smoking and limit alcohol consumption, because tobacco and alcohol may increase the burden on the liver or affect the efficacy of medications.

In addition, patients should maintain a good attitude, follow up regularly, follow the doctor's arrangements for imaging and laboratory examinations, and timely evaluate drug efficacy and adverse reactions. For patients taking medication for a long time, special attention should be paid to bone health and nutritional supplements to prevent the effects of chronic side effects.

6. Summary of key reminders

As the first targeted drug for the KRAS G12C mutation, sotoracib brings a breakthrough treatment option to patients, but it must be based on accurate detection, strict follow-up and scientific management. Patients should pay attention to the following points while taking medication:

Confirm the genetic mutation status and take medication as directed by your doctor;

Take it strictly according to the dose and time, and avoid missing doses or increasing the dose at will;

Regularly monitor liver function, lung function and blood routine, and report abnormal symptoms in a timely manner;

Be wary of drug interactions and avoid combining other drugs on your own;

Maintain a healthy lifestyle and actively cooperate with follow-up and imaging evaluations.

To sum up, sotorasiib not only represents a new direction in the treatment of KRAS mutations, but also puts forward higher requirements for patient compliance and management. Only when used scientifically and rationally under the guidance of a doctor can its efficacy be maximized and the patient's long-term survival and quality of life guaranteed.

Reference link:https://www.drugs.com